| Authors: |
Harrison SJ; Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, Victoria, Australia., Perrot A; Centre Hospitalo-universitaire (CHU) de Toulouse, Institut Universitaire du Cancer de Toulouse-Oncopole (IUCT-O), Université de Toulouse, UPS, Service d'Hématologie, Toulouse, France., Alegre A; University Hospital La Princesa and University Hospital Quironsalud, Madrid, Spain., Simpson D; North Shore Hospital, Auckland, New Zealand., Wang MC; Chang Gung Medical Foundation, Taipei, Taiwan., Spencer A; The Alfred Hospital, MONASH University/Australian Centre for Blood Diseases, Melbourne, Victoria, Australia., Delimpasi S; Evangelismos Hospital, Athens, Greece., Hulin C; Service d'Hématologie Hôpital Haut-Lévêque CHU, Bordeaux, France., Sunami K; Department of Hematology, National Hospital Organization Okayama Medical Center, Okayama, Japan., Facon T; Department of Haematology, Lille University Hospital, Lille, France., Vlummens P; Department of Haematology, Ghent University Hospital, Ghent, Belgium., Yong K; Department of Haematology, University College Hospital, London, UK., Campana F; Sanofi, Cambridge, MA, USA.; Affiliation at time of study, currently Takeda Pharmaceuticals, Cambridge, MA, USA., Inchauspé M; IT&M Stats (for Sanofi), Neuilly-sur-Seine, Île-de-France, France., Macé S; Sanofi R&D, Vitry-sur-Seine, France., Risse ML; Sanofi R&D, Vitry-sur-Seine, France., van de Velde H; Sanofi, Cambridge, MA, USA., Richardson P; Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA. |
